

ASX Announcement

Race Completes On-Market Buy-Back Program

22 June 2023 – Race Oncology (ASX: RAC) advises that it has completed its on-market share buy-back program.

The Company announced on 9 June 2022 that it intended to buy back up to 4 million Race Oncology ordinary shares across a period of up to 12 months. Over the course of the buy-back, Race has acquired 634,881 shares for a total consideration of approximately \$1,276,598 (including brokerage costs). The acquired shares have been cancelled and the total number of outstanding ordinary shares in the Company following the completion of the buy-back is 163,068,780.

The 12-month buy-back period has now expired and is not being renewed. Race has many exciting programs and will concentrate its capital by advancing bisantrene clinical development as efficiently and rapidly as possible.

The ASX final buy-back notification will be lodged with the ASX immediately following this announcement and will also be made available via the Race Oncology website.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase 2/3 cancer drug called bisantrene.

Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

In breakthrough preclinical research, Race has also discovered that bisantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target cancer.

The Company also has compelling clinical data for bisantrene as a chemotherapeutic agent and is in multiple clinical trials in Acute Myeloid Leukaemia (AML).

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of bisantrene. Learn more at www.raceoncology.com



If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Damian Clarke-Bruce, CEO/MD on behalf
of the Race Board of Directors
damian.clarke-bruce@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au